Drug Delivery

Superior results reported with CAP vaccines

Published in Vaccine Weekly, September 17th, 2003

BioSante Pharmaceuticals, Inc., (BISP) announced results of several studies demonstrating the superiority of its innovative calcium phosphate nanoparticulate (CAP) vaccine adjuvant and delivery system, BioVant, compared to the only approved adjuvant, aluminum salts (alum).

The results were presented at the 6th annual Conference on Vaccine Research in Arlington, Virginia. The company also recently announced a cooperative research and development agreement (CRADA) with the U.S. Army to use the new technology in the development of biodefense vaccines.

In the reported studies, BioVant was combined with antigens from the Epstein-Barr virus (EBV), the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-09-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry